Aprea Therapeutics (NASDAQ:APRE) Given New $3.00 Price Target at Wedbush

Aprea Therapeutics (NASDAQ:APRE) had its price objective lowered by equities research analysts at Wedbush from $6.00 to $3.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Wedbush’s price objective points to a potential upside of 339.24% from the stock’s current price.

A number of other analysts also recently issued reports on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aprea Therapeutics in a research note on Friday, July 17th. Oppenheimer began coverage on Aprea Therapeutics in a research note on Thursday, May 7th. They set an “outperform” rating and a $5.00 price target for the company. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Aprea Therapeutics currently has an average rating of “Hold” and a consensus target price of $3.07.

Aprea Therapeutics Stock Performance

APRE stock opened at $0.68 on Thursday. The company’s fifty day moving average price is $0.71 and its 200-day moving average price is $0.77. Aprea Therapeutics has a one year low of $0.55 and a one year high of $1.79. The company has a market capitalization of $8.46 million, a PE ratio of -0.44 and a beta of 1.52.

Aprea Therapeutics (NASDAQ:APRE) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.11. Aprea Therapeutics had a negative net margin of 4,405.59% and a negative return on equity of 61.03%. On average, research analysts predict that Aprea Therapeutics will post -0.84 EPS for the current fiscal year.

Institutional Investors Weigh In On Aprea Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. DRW Securities LLC purchased a new stake in shares of Aprea Therapeutics during the 4th quarter valued at $103,000. Jane Street Group LLC purchased a new stake in shares of Aprea Therapeutics during the fourth quarter valued at $40,000. Finally, AIGH Capital Management LLC increased its position in shares of Aprea Therapeutics by 174.1% in the 1st quarter. AIGH Capital Management LLC now owns 1,015,541 shares of the company’s stock valued at $775,000 after acquiring an additional 645,000 shares during the period. Hedge funds and other institutional investors own 34.19% of the company’s stock.

Aprea Therapeutics Company Profile

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.